Document Detail

Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension.
MedLine Citation:
PMID:  19618317     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Increased sympathetic activity might be related to pathogenesis of hypertension as well as to end organ damage. Animal studies suggest that statins decrease sympathetic activity and increase baroreceptor reflex sensitivity (BRS). AIM: To examine whether atorvastatin decreases muscle sympathetic nerve activity (MSNA) and BRS in hypercholesterolaemic and hypertensive patients. METHODS: Ten patients with essential hypertension and untreated hypercholesterolaemia (aged 43 +/- 12 years) and eight healthy subjects (aged 37 +/- 7 years) were enrolled in the study. In both groups the recordings of microneurography, ECG, blood pressure and BRS were performed twice, before and after 8 weeks during which the patients (but not controls) were treated with atorvastatin. RESULTS: Compared with controls, the patients had higher MSNA values (36.0 +/- 6.6 vs. 29.8 +/- 3.7 bursts/minute), mean BP levels (145.1 +/- 10 vs. 124.1 +/- 11.1 mmHg) and total cholesterol concentration (252.6 +/- 22.6 vs. 179.8 +/- 20.7 mg/dl) baseline values. Statin therapy resulted in a decrease of total cholesterol (252.6 +/- 22.0 vs. 173.8 +/- 26.2 mg/dl, p < 0.05) and MSNA (36.0 +/- 6.6 vs. 28.6 +/- 4.8 bursts/min, p < 0.05), whereas BRS values were increased (12.6 +/- 5.6 vs. 18.1 +/- 5.9 ms/mmHg, p < 0.05). Post-treatment BRS was inversely related to post-treatment MSNA (r = -0.73, p < 0.05). In the controls there were no changes in MSNA (29.8 +/- 3.7 vs. 28.9 +/- 2.9 bursts/min), BRS (11.9 +/- 5.0 vs. 13.1 +/- 4.8 ms/mmHg), total cholesterol, BP and heart rate between the first and the second measurement. CONCLUSION: Atorvastatin reduces MSNA and increases BRS in hypertensive and hypercholesterolaemic patients. Decrease in sympathetic activity may be the result of improvement of baroreceptor function by atorvastatin.
Maciej Siński; Jacek Lewandowski; Agnieszka Ciarka; Joanna Bidiuk; Piotr Abramczyk; Anna Dobosiewicz; Zbigniew Gaciong
Related Documents :
24021617 - Could pin1 help us conquer essential hypertension at an earlier stage? a promising earl...
24352797 - 2014 evidence-based guideline for the management of high blood pressure in adults: repo...
23863317 - Effects of ace and add1 gene polymorphisms on blood pressure response to hydrochlorothi...
24784167 - Hypertension detection, management, control and associated factors among residents acce...
6795167 - Occlusion pressures during the ventilatory response to hypoxemia in the newborn monkey.
21983107 - Theoretical and experimental studies on the internal mobility of two sulfonylurea agent...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Kardiologia polska     Volume:  67     ISSN:  0022-9032     ISO Abbreviation:  Kardiol Pol     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-07-20     Completed Date:  2009-10-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376352     Medline TA:  Kardiol Pol     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  613-20     Citation Subset:  IM    
Warszawski Uniwersytet Medyczny, Banacha 1a, 02-097 Warszawa, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticholesteremic Agents / therapeutic use*
Baroreflex / drug effects*
Heptanoic Acids / therapeutic use*
Hypercholesterolemia / complications,  drug therapy*
Hypertension / complications*
Pressoreceptors / drug effects
Pyrroles / therapeutic use*
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Heptanoic Acids; 0/Pyrroles; 110862-48-1/atorvastatin
Comment In:
Kardiol Pol. 2009 Jun;67(6):621-2   [PMID:  19852090 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Interleukin-1b and interleukin-1 receptor inhibitor gene cluster polymorphisms in patients with coro...
Next Document:  Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 m...